<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02032264</url>
  </required_header>
  <id_info>
    <org_study_id>RMA-2013-04</org_study_id>
    <nct_id>NCT02032264</nct_id>
  </id_info>
  <brief_title>Next Generation Sequencing Screening for Embryonic Ploidy Status</brief_title>
  <acronym>nexgen</acronym>
  <official_title>Evaluation of the Efficacy of Next Generation Sequencing in Predicting Embryonic Karyotype and Subsequent Pregnancy Outcomes in in Vitro Fertilization Cycles (IVF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reproductive Medicine Associates of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Reproductive Medicine Associates of New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the benefits of using next generation sequencing to assess embryonic aneuploidy.
      All viable blastocysts will be biopsied and cryopreserved for future transfer. After the
      final embryo is cryopreserved, patients will be randomized to either the intervention group
      or the control group. Patients and doctors are blinded to the randomization until study
      completion. A Double Embryo Transfer (DET) will be performed with either screened or
      unscreened embryos depending on randomization. A Single Embryo Transfer (SET) may occur in
      cases where only one embryo is available for transfer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Impact of next generation sequencing on the embryos produced from IVF on implantation rates</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate the benefits, if any, of using next generation sequencing based Comprehensive Chromosome Screening (CCS) in the selection of embryos for transfer during clinical IVF cycles</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Delivery Rates</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">309</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Comprehensive Chromosome Screening</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trophectoderm biopsy will be performed on all blastocysts and CCS via next generation sequencing screening performed on biopsy samples. Patients will proceed with a single or double embryo transfer of the one or two morphologically best euploid embryos</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Comprehensive Chromosome Screening</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patients in this group will proceed with a single or double embryo transfer of the one or two morphologically best embryos.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Comprehensive Chromosome Screening</intervention_name>
    <description>On day 6 of embryo development, all embryos will undergo a trophectoderm biopsy using the standardized technique, as according to standard laboratory protocol and without regard to study. Comprehensive Chromosome Screening (CCS), will be performed via next generation sequencing and results will be available at the time of study completion.</description>
    <arm_group_label>Comprehensive Chromosome Screening</arm_group_label>
    <other_name>PGD</other_name>
    <other_name>CCS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Morphologically Best</intervention_name>
    <description>Patients in this arm of the study will not receive CCS in selection of their embryo for transfer. The best looking embryo (morphology) will be transferred</description>
    <arm_group_label>No Comprehensive Chromosome Screening</arm_group_label>
    <other_name>Unscreened</other_name>
    <other_name>No CCS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient undergoing IVF/CCS (no PGD banking)

          -  Patient meets ASRM guidelines for Double Embryo Transfer (DET)

          -  Donor Sperm OK

          -  AMH ≥ 1.2

          -  FSH ≤ 12

          -  BAFC ≥12

          -  Max 1 prior failed IVF cycle for patients 35-45 years old

          -  Patient &lt;35 years old MUST have 1 prior failed IVF cycle

        Exclusion Criteria:

          -  Chronic endometrial insufficiency

          -  Use of oocyte donor or gestational carriers

          -  Medical contraindications to Double Embryo Transfer (DET)

          -  Male Factor (&lt;100,000 sperm or surgical sperm)

          -  Communicating hydrosalpinx (on HSG)

          -  Single gene disorders or sex selection
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard T Scott, M.D., HCLD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Reproductive Medicine Associates of New Jersey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Reproductive Medicine Associates of New Jersey</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.rmanj.com/</url>
    <description>Reproductive Medicine Associates of New Jersey</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2014</study_first_submitted>
  <study_first_submitted_qc>January 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2014</study_first_posted>
  <last_update_submitted>March 16, 2017</last_update_submitted>
  <last_update_submitted_qc>March 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Next generation sequencing</keyword>
  <keyword>Embryonic aneuploidy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

